- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | To Wall Street, a new bidding war puts Alkermes in a tough spot | ||
| Fr | Bristol Myers, J&J's new blood thinner fails first big test | ||
| Fr | Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal | ||
| Fr | Merck stakes $9.2B on Cidara and its long-acting flu drug | ||
| Fr | Medicxi closes fifth fund to back 'asset-centric' startups | ||
| Do | Day One snaps up ADC maker Mersana in backloaded buyout deal | ||
| Do | Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing | ||
| Mi | Novartis, with study success, to seek approval of new kind of malaria drug | ||
| Mi | FDA unveils new regulatory roadmap for bespoke drug therapies | ||
| Mi | Richard Pazdur, longtime FDA oncology leader, to head agency's main drug office | ||
| Mi | Metagenomi, Ovid CEOs step aside; Cogent soars on 'unprecedented' stomach cancer data | ||
| Di | Neurocrine chalks up a depression drug failure | ||
| 10.11. | FDA to remove safety warnings on hormonal menopause therapy | ||
| 10.11. | Roche's MS tablet scores in late-stage studies | ||
| 10.11. | Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots | ||
| 10.11. | Lilly picks up an eye gene therapy in deal with MeiraGTx | ||
| 07.11. | CMS to launch model to lower Medicaid drug spending | ||
| 07.11. | Patient dies in Intellia trial; FDA awards 6 more 'national priority' vouchers | ||
| 07.11. | Pharma's clinical trial diversity push faces a new threat | ||
| 06.11. | Novo, Lilly cut deal with Trump to lower prices of obesity drugs | ||
| 06.11. | AstraZeneca exercises option to buy an obesity startup | ||
| 06.11. | Moderna leans on cost cuts, pipeline as vaccine sales dip | ||
| 06.11. | J&J brain drug acquired in $14.6B buyout cleared for broader use | ||
| 06.11. | Evommune nabs $150M in IPO amid federal shutdown | ||
| 05.11. | Knocked back by the FDA, Biohaven turns to major cost cuts |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .